Neurological complications in β-thalassemia

Brain and Development

Volumn 28, Issue 8, 2006, Pages 477-481

  Zafeiriou, Dimitrios I ^a   Economou, Marina ^a   Athanasiou Metaxa, Miranta ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Thalassemia; Abnormalities; Complications; Evoked potentials; Nerve conduction velocities; Neurological; Neurophysiological; Neuropsychological; Neurotoxicity; Subclinical

Indexed keywords

CYANOCOBALAMIN; DEFEROXAMINE; IRON;

ABSENTEEISM; AGING; AWARENESS; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PATHWAY; CORRELATION ANALYSIS; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EVOKED AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; FAMILY ATTITUDE; FOLIC ACID DEFICIENCY; HEMOSIDEROSIS; HOSPITALIZATION; HUMAN; HYPOXIA; INTELLIGENCE QUOTIENT; IRON OVERLOAD; LIFE EXPECTANCY; MENTAL HEALTH; MUSCLE WEAKNESS; MYALGIA; NERVE CONDUCTION; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NEUROPSYCHOLOGY; NEUROTOXICITY; NUTRITIONAL DEFICIENCY; OTOTOXICITY; PANCREAS; PARESTHESIA; PATIENT CARE; PATIENT MONITORING; PERCEPTION DEAFNESS; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PREVALENCE; PROTECTION; QUALITY OF LIFE; RECORDING; RISK FACTOR; SHORT SURVEY; SOCIAL BEHAVIOR; SYMPTOMATOLOGY; VISUAL IMPAIRMENT;

ANOXIA; BETA-THALASSEMIA; EVOKED POTENTIALS; HEMOSIDEROSIS; HUMANS; NERVOUS SYSTEM DISEASES; NEURAL CONDUCTION; NEUROPHYSIOLOGY; NEUROPSYCHOLOGY; NEUROTOXICITY SYNDROMES;

EID: 33745900221     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2006.02.005     Document Type: Short Survey

References (60)

1. Fosburg M., and Nathan D. Treatment of Cooley's anemia. Blood 76 (1990) 435-444
2. Zurlo M., De Stefano P., Borna-Pignatti C., Di Palma A., Piga A., Melevendi C., et al. Survival and causes of death in thalassemia major. Lancet 2 (1989) 27-30
3. Modell B., Khan M., and Darlison M. Survival in beta-thalassemia major in the UK: Data from the UK Thalassemia Register. Lancet 355 (2000) 2051-2052
4. Anderson L., Holden S., Davis B., Prescott E., Charrier C., Bunce N., et al. Cardiovascular T2-star magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001) 2171-2179
5. Aarabi B., Haghshenas M., and Rakeii V. Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia: case report. Neurosurgery 42 (1998) 922-925
6. Sorcinelli R., Cacace E., and Del Piano M. Optic nerve compression by extramedullary hematopoietic tissue in a patient suffering from beta-thalassemia intermedia. Metab Pediatr Syst Ophthalmol 22-23 (1999-2000) 5-6
7. Meara J., Potter C., Goodman M., and Vernick D. Extramedullary hematopoiesis of the middle ear in a patient with thalassemia. Am J Otolaryngol 19 (1998) 287-289
8. Chehal A., Aoun E., Koussa S., Skoury H., and Taher A. Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine 28 (2003) E245-E249
9. Salehi S., Koski T., and Ondra S. Spinal cord compression in beta-thalassemia: case report and review of literature. Spinal Cord 42 (2004) 117-123
10. Niggemann P., Krings T., Hans F., and Thron A. Fifteen year follow up of a patient with beta-thalassemia and extramedullary haemopoietic tissue compressing the spinal cord. Neuroradiology 47 (2005) 263-266
11. Saxon B., Ress D., and Olivieri N. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassemia. Br J Haematol 101 (1998) 416-419
12. Saghafi M., Shirdel A., and Lari S. Extramedullary hematopoiesis with spinal cord compression in beta-thalassemia intermedia. Eur J Intern Med 16 (2005) 596-597
13. Aliberti B., Patrikiou A., Terentiou A., Fragatou S., and Papadimitriou A. Spinal cord compression due to extramedullary haematopoiesis in two patients with thalassemia: complete regression with blood transfusion therapy. J Neurol 248 (2001) 18-22
14. Cianciulli P., di Toritto T., Sorrentino F., Sergiacomi L., Massa A., and Amadori S. Hydroxyurea therapy in paraparesis and cauda equina syndrome due to extramedullary haematopoiesis in thalassemia: improvement of clinical and haematological parameters. Eur J Haematol 64 (2000) 426-429
15. Stamboulis E., Vlachou N., Drossou M., Tsaftaridis P., Koutsi G., Katsaros N., Economou-Petersen E., and Loutradi-Anagnostou A. Axonal sensorimotor neuropathy in patients with beta-thalassemia. J Neurol Neurosurg Psychiatry 75 (2004) 1483-1486
16. Incorpora G., Di Gregorio F., Romeo M., Pavone P., Trifiletti R., and Paranao E. Focal neurological deficits in children with beta-thalassemia major. Neuropediatrics 30 (1999) 45-48
17. Manfre L., Giarratano E., Maggio A., Banco A., Vaccaro G., and Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. Am J Roentgenol 173 (1999) 1477-1480
18. Moratelli S., De Sanctis V., Gemmati D., Serino M., Mari R., Gamberini M., et al. Thrombotic risk in thalassemic patients. J Pediatric Endocrinol Metab 11 Suppl. 3 (1998) 915-921
19. Singh R., and Venketasubramanian N. Recurrent cerebral infarction in beta-thalassemia major. Cerebrovasc Dis 17 (2004) 344-345
20. Sebire G., Tabarki B., Saunders D., Leroy I., Liesner R., Saint-Martin C., et al. Cerebral venus sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain 128 (2005) 477-489
21. Giordano P., Del Vecchio G., Altomare M., Coppola B., Schettini F., Iolacson A., et al. Resistance to activated protein C in thalassemic patients: an underlying cause of thrombosis. Eur J Haematol 61 (1998) 123-127
22. Eldor A., Durst R., Hy-Am E., Goldfarb A., Gillis S., Rachmilewitz E., et al. A chronic hypercoagulable state in patients with beta-thalasemia major is already present in childhood. Br J Haematol 107 (1999) 739-746
23. Capellini M., Robbiolo L., Botasso B., Coppola R., Fiorelli G., and Manucci A. Venus thromboembolism and hypercoagulability in splenectomized patients with thalassemia intermedia. Br J Haematol 111 (2000) 467-473
24. Caksen H., Odabas D., Akbayram S., Faik Oner A., Arslan S., Cesur Y., et al. Silent stroke in a case of beta-thalassemia major associated with chronic renal failure and diabetes mellitus. J Child Neurol 18 (2003) 798-800
25. De Virgiliis S., Argiolu F., Sanna G., Cornacchia G., Cossu P., Cao A., et al. Auditory involvement in thalassemia major. Acta Haematol 61 (1979) 209-215
26. Gelmi C., Borgna-Pignatti C., Franchin S., Tacchini M., and Trimarchi F. Electroretinographic and visual evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica 196 (1988) 29-34
27. Metafratzi A., Argyropoulou M., Kiortsis D., Tsampoulas C., Chaliassos N., and Efremidis S. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassemia major. Br J Radiol 74 (2001) 407-410
28. Antonini A., Leenders K., Meier D., Oertel W., Boesiger P., and Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 43 (1993) 697-700
29. Oba H., Araki T., and Ohtomo K. Amyotrophic lateral sclerosis. T2 shortening in motor cortex at MR imaging. Radiology 189 (1993) 843-846
30. Monastero R., Monastero G., Ciaccio C., Padovani A., and Camarda R. Cognitive deficits in beta-thalassemia major. Acta Neurol Scand 102 (2000) 162-168
31. Wong V., Li A., and Lee A. Neurophysiological study of beta-thalassemia patients. J Child Neurol 8 (1993) 330-335
32. Porter J., Jawson M., Huehns E., East C., and Hazell J. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 73 (1989) 403-409
33. De Virgiliis S., Congia M., Turco M., Frau F., Dessi C., Argiolou F., et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassemia. Arch Dis Child 63 (1988) 250-255
34. Klebanoff S., Waltersdorph A., Michel B., and Rosen H. Oxygen based free radical generation by ferrous ions and deferoxamine. J Biol Chem 264 (1989) 19765-19771
35. Ambrosetti U., Donde E., Piatti G., and Capellini M. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res 42 (2000) 485-487
36. Olivieri N., Buncic J., Chew E., Gallant T., Harrison R., Keenan N., et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. New Engl J Med 314 (1986) 869-873
37. Amabile G., Stefano E., Bianco I., Aliquo M., Giunti P., and Pierelli F. Electrophysiologic study in patients with beta-thalassemia major. Acta Neurol 87 (1987) 181-190
38. Sacco M., Meleleo D., Tricarico N., Greco Miani A., Serra E., and Parlatone L. Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results. Minerva Pediatr 46 (1994) 225-230
39. Chiodo A., Alberti P., Sher G., Francombe W., and Tayler B. Desferrioxamine ototoxicity in an adult transfusion dependent population. J Otolaryngol 26 (1997) 116-122
40. Porter J. A risk-benefit assessment of iron-chelation therapy. Drug Saf 17 (1997) 407-421
41. Orton R., De Veber L., and Sulh H. Ocular and auditory toxicity of long-term high dose subcutaneous deferoxamine therapy. Can J Ophthalmol 20 (1985) 153-156
42. Kontzoglou G., Koussi A., Economou M., Tsatra I., Perifanis V., Noussios G., and Athanassiou-Metaxa M. Long term audiological evaluation of beta-thalassemic patients. Acta Otorhinolaryngol Belg 58 (2004) 113-117
43. Styles A., and Vichinsky E. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine. J Pediatr Hematol Oncol 18 (1996) 42-45
44. Marciani M., Cianciulli P., Stefani N., Stefanini F., Peroni L., Sabbadini M., et al. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual vision. Haematologica 76 (1991) 131-134
45. Triantafyllou N., Fisfis M., Sideris G., Triantafyllou G., Rombos A., Vrettou A., et al. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine treatment. Acta Neurol Scand 83 (1991) 306-308
46. Higgs D.R., Thein S.L., and Wood W.G. The pathology of the thalassemias. In: Weatherall D.J., and Clegg J.B. (Eds). The thalassemia syndromes. 4th ed. (2001), Blackwell Science, Oxford 192-236
47. Giardina P., Nealon N., and McQueen M. Sensorimotor neuropathy associated with high dose desferrioxamine. Blood 78 (1991) 199-205
48. Levine J., Cohen A., Mac Queen M., Martin M., and Giardina P. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment. J Pediatr Hematol Oncol 19 (1997) 139-141
49. Zafeiriou D., Koussi A., Tsantali C., Kontopoulos E., Augoustidou P., Tsoubaris D., et al. Neurophysiological evaluation of long-term desferrioxamine therapy in beta-thalassemia patients. Pediatr Neurol 18 (1998) 420-424
50. Economou M., Zafeiriou D., Kontopoulos E., Gompakis N., Koussi A., Perifanis V., and Athanassiou-Metaxa M. Neurophysiologic and intellectual evaluation of beta-thalassemia patients. Brain Dev 28 (2006) 14-18
51. Robinson R. Subacute combined system degeneration in Cooley's anemia: excessive vitamin B12 utilization producing a relative deficiency combined system degeneration. J Indiana State Med Assoc 69 (1976) 735-737
52. Vatanavicharn S., Anuvatanakulchai M., Na-Nakorn S., and Wasi P. Serum erythrocyte folate levels in thalassemic patients in Thailand. Scand J Haematol 22 (1979) 241-245
53. Luhby A., Cooperman J., Feldman R., Ceraolo J., Herrero J., and Marley J. Folic acid deficiency as a limiting factor in the anemias of thalassemia major. Blood 18 (1961) 786
54. Pippard M., Rajagopalan B., Callender S., and Weatherall D. Iron loading, chronic anemia, and erythroid hyperplasia as determinants of the clinical features of beta-thalassemia intermedia. In: Weatherall D., Fiorelli G., and Gorini S. (Eds). Advances in red blood cell biology (1982), Raven Press, New York
55. Arcasov A., Canata D., Sinav B., Kutlav L., Oguz N., and Sen M. Serum zinc levels and zinc binding capacity in thalassemia. J Trace Elem Med Biol 15 (2001) 85-87
56. Aydinok Y., Coker C., Kavakli K., Polat A., Nisli G., Cetiner N., et al. Urinary zinc excretion and zinc status of patients with beta-thalassemia major. Biol Trace Elem Res 70 (1999) 165-172
57. Pall H., Blake D., Winyard P., Lunec J., Williams A., Good P., et al. Ocular toxicity of desferrioxamine-an example of copper promoted auto-oxidative damage?. Br J Ophthalmol 73 (1989) 42-47
58. Lakhanpal V., Schocket S., and Jiji R. Deferoxamine induced toxic retinal pigmentary degeneration and optic neuropathy. Ophthalmology 91 (1984) 443-451
59. Papanastasiou D., Papanicolaou D., Magiakou A., Beratis N., Tzebelikos E., and Papapetropoulos T. Peripheral neuropathy in patients with beta-thalassemia. J Neurol Neurosurg Psychiatry 54 (1991) 997-1000
60. Wechsler D. Wechsler intelligence scale for children. 3rd ed. (1991), The Psychological Corp., San Antonio (TX)